ACHIEVEMENT OF LOW DISEASE ACTIVITY IN PATIENTS INITIATING INFLIXIMAB WITH AND WITHOUT DOSE ESCALATION

被引：0
作者：
Cohen, S. [1 ]
Reed, G. [2 ]
Magner, R. [3 ]
Kafka, S. [4 ]
Ellis, L. [4 ]
DeHoratius, R. J. [5 ]
Greenberg, J. D. [6 ]
机构：
[1] Metroplex Clin Res Ctr, Dallas, TX USA
[2] LLC Mass Med Sch, Corrona, Southborough, MA USA
[3] U Mass Med Sch, Worcester, MA USA
[4] Janssen Sci Affairs LLC, Horsham, PA USA
[5] Horsham Phila, LLC Kimmel Sch Med, Janssen Sci Affairs, Horsham, PA USA
[6] NYU, LLC, Sch Med, Corrona, Southborough, NY USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2016年 / 75卷
关键词：
D O I：
10.1136/annrheumdis-2016-eular.2771
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0156
引用
收藏
页码：238 / 239
页数：2
相关论文
共 50 条
[41]   Comparative Outcomes of Adalimumab and Infliximab Dose Escalation in Inflammatory Bowel Disease Patients Failing First-Line Biologic Treatment [J].
Atay, Ali ;
Cagir, Yavuz ;
Ergul, Mucahit ;
Ozturk, Oguz ;
Durak, Muhammed Bahaddin ;
Yuksel, Ilhami .
JOURNAL OF CLINICAL MEDICINE, 2025, 14 (04)
[42]   Insurance Approval Delay of Biologic Therapy Dose Escalation Associated with Disease Activity in Patients with Inflammatory Bowel Disease [J].
Shah, Nisha B. ;
Zuckerman, Autumn D. ;
Hosteng, Katie R. ;
Fann, Jessica ;
Declercq, Josh ;
Choi, Leena ;
Cherry, Laura ;
Schwartz, David A. ;
Horst, Sara .
DIGESTIVE DISEASES AND SCIENCES, 2023, 68 (12) :4331-4338
[43]   Insurance Approval Delay of Biologic Therapy Dose Escalation Associated with Disease Activity in Patients with Inflammatory Bowel Disease [J].
Nisha B. Shah ;
Autumn D. Zuckerman ;
Katie R. Hosteng ;
Jessica Fann ;
Josh DeClercq ;
Leena Choi ;
Laura Cherry ;
David A. Schwartz ;
Sara Horst .
Digestive Diseases and Sciences, 2023, 68 :4331-4338
[44]   Efficacy of Infliximab Dose Escalation in Patients With Refractory Immunotherapy-Related Colitis: A Case Series [J].
Harris, Jessica P. ;
Faleck, David .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 :S1688-S1688
[45]   Efficacy of Infliximab Dose Escalation in Patients with Refractory Immunotherapy-Related Colitis: A Case Series [J].
Harris, Jessica P. ;
Postow, Michael A. ;
Faleck, David M. .
ONCOLOGIST, 2022, 27 (04) :E350-E352
[46]   Efficacy and safety of dose escalation of infliximab therapy in Japanese patients with psoriasis: Results of the SPREAD study [J].
Torii, Hideshi ;
Nakano, Masayuki ;
Yano, Toshiro ;
Kondo, Kazuoki ;
Nakagawa, Hidemi .
JOURNAL OF DERMATOLOGY, 2017, 44 (05) :552-559
[47]   EFFICACY OF INFLIXIMAB DOSE ESCALATION IN PATIENTS WITH REFRACTORY IMMUNOTHERAPY-RELATED COLITIS: A CASE SERIES [J].
Harris, Jessica ;
Faleck, David .
GASTROENTEROLOGY, 2021, 160 (03) :S79-S80
[48]   Dose Escalation Among Rheumatoid Arthritis Patients Treated with Infliximab or Abatacept: Comparison in Claims Data [J].
Darkow, Theodore ;
Chastek, Benjamin ;
Rosenblatt, Lisa ;
Trivedi, Digisha ;
Hebden, Tony ;
Henk, Henry ;
Liu, Fang .
ARTHRITIS AND RHEUMATISM, 2011, 63 (10) :S476-S476
[49]   EFFICACY OF INFLIXIMAB DOSE ESCALATION IN PATIENTS WITH REFRACTORY IMMUNOTHERAPY-RELATED COLITIS: A CASE SERIES [J].
Harris, Jessica ;
Faleck, David .
INFLAMMATORY BOWEL DISEASES, 2021, 27 :S58-S58
[50]   High treatment persistence following infliximab dose escalation in Inflammatory Bowel Disease: A real world study [J].
Salehi, O. ;
Gondal, F. ;
Terlato, M. ;
Pillay, L. ;
Macrae, F. ;
Rentsch, C. ;
Dimkovski, S. ;
Segal, J. P. .
JOURNAL OF CROHNS & COLITIS, 2025, 19 :i1174-i1174
12345